ArticleJournal of translational medicine2026
Umbilical cord-derived mitochondrial transplantation restores tendon structure and function in a preclinical model of achilles tendinopathy.
Article in Journal of translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundAchilles tendinopathy is a degenerative musculoskeletal disorder for which disease-modifying therapies remain limited, largely due to the inability of current interventions to directly restore cellular bioenergetic function. Emerging evidence has identified mitochondrial dysfunction as a central contributor to tendon degeneration, highlighting mitochondria as a potential therapeutic target. Here, we evaluated umbilical cord-derived mitochondria (UC-MT) as a dose-defined, cell-free therapeutic strategy for tendinopathy.
methodsUC-MT were isolated from human umbilical cord-derived mesenchymal stem cells and characterized for mitochondrial integrity and bioenergetic activity. Therapeutic efficacy was evaluated in vitro using TNF-α-induced human tenocyte injury models and in vivo in a collagenase-induced rat model of Achilles tendinopathy. Dose-response effects were systematically assessed (5, 10, and 20 µg), and mitochondrial function, metabolic profiles, extracellular matrix remodeling, and functional recovery were analyzed using integrated molecular, histological, and functional assays, including transcriptomic and metabolomic profiling.
resultsUC-MT treatment significantly restored mitochondrial membrane potential, ATP production, and respiratory complex activity in injured tenocytes, accompanied by attenuation of inflammatory signalling. Among the tested doses, 10 µg UC-MT consistently produced the most robust therapeutic effects across mitochondrial, metabolic, and structural outcome measures. In vivo, UC-MT administration improved tendon histoarchitecture, collagen organization, and functional performance, while integrated multi-omics analyses revealed coordinated metabolic reprogramming, including restoration of mitochondrial complex I-linked bioenergetic pathways.
conclusionsTaken together, these findings position UC-MT as a dose-defined, cell-free therapeutic modality with translational potential for tendon regeneration. By directly targeting mitochondrial dysfunction, UC-MT restores mitochondrial bioenergetics and supports tendon regeneration in preclinical models of tendinopathy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.